These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8558183)

  • 1. Finally, a successful adjuvant therapy for high-risk melanoma.
    Balch CM; Buzaid AC
    J Clin Oncol; 1996 Jan; 14(1):1-3. PubMed ID: 8558183
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant IFN alpha2 therapy of melanoma.
    Kirkwood JM
    Lancet; 1998 Jun; 351(9120):1901-3. PubMed ID: 9654253
    [No Abstract]   [Full Text] [Related]  

  • 3. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Malignant melanoma].
    Schmid-Wendtner M; Wendtner CM
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2548-50. PubMed ID: 23188634
    [No Abstract]   [Full Text] [Related]  

  • 5. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 6. [Interferon therapy in malignant melanoma].
    Kokoschka EM; Micksche M
    Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
    Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
    Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus conference. Follow-up of patients surgically treated for stage I melanoma].
    Ann Dermatol Venereol; 1995; 122(5):250-8. PubMed ID: 8572461
    [No Abstract]   [Full Text] [Related]  

  • 9. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant interferon alfa-2b for high-risk melanoma.
    Retsas S
    J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy of melanoma.
    Retsas S
    Lancet; 1998 Aug; 352(9129):737-8. PubMed ID: 9729017
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 14. Favorable prognostic factors in recurrent and metastatic melanoma.
    Buzzell RA; Zitelli JA
    J Am Acad Dermatol; 1996 May; 34(5 Pt 1):798-803. PubMed ID: 8632077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of local magnitothermia in the treatment of patients with primary-confined skin melanoma].
    Korovin SI; Tolstopiatov BA; Medinets IuR; Protsenko VV; Dedkov AG; Palivets AIu; Smakova MS
    Lik Sprava; 2002; (1):129-33. PubMed ID: 11944360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The adjuvant therapy of malignant melanoma].
    Hauschild A; Sterry W
    Dtsch Med Wochenschr; 1992 Feb; 117(8):303-6. PubMed ID: 1537268
    [No Abstract]   [Full Text] [Related]  

  • 17. Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma.
    Swetter SM
    J Am Acad Dermatol; 2016 Sep; 75(3):525-527. PubMed ID: 27317056
    [No Abstract]   [Full Text] [Related]  

  • 18. Malignant melanoma and the sentinel lymph node biopsy.
    Kuhn JA; McCarty TM
    Cancer Invest; 1999; 17(1):39-46. PubMed ID: 10999048
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
    Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
    Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.